# **BIO-RAD LABORATORIES INC.**

ISIN: US0905722072 WKN: 090572207 Asset Class: Stock

rad.com

E-mail: ask customer care@bio-



### **Company Profile**

94547 Hercules

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

#### Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 3,048,330,000 3,157,976,000 1,989,088,000 Common stock capital 3,000 **Fixed assets** 9,250,740,000 10,343,690,000 15,786,707,000 Equity capital of a company 8,741,133,000 9,615,252,000 13,667,134,000 403 966 000 434 228 000 470 797 000 Cash and cash equivalents Accrued liabilities 900.000 0 400.000 Other assets **Current liabilities** 522,799,000 568.708.000 680.938.000 Prepayments and accrued income Non-current liabilities 3,035,138,000 3,317,706,000 3,427,723,000 Different income Other liabilities

| Other liabilities   |                | 194,213,000    |                | 185,812,000    |                | 171,291,000    |
|---------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Total assets        | 12,299,070,000 | 12,299,070,000 | 13,501,666,000 | 13,501,666,000 | 17,775,795,000 | 17,775,795,000 |
|                     |                |                |                |                |                |                |
| Balance notes       |                |                |                |                |                |                |
|                     |                |                |                | 2023           | 2022           | 2021           |
| Accounting standard |                |                | ı              | US-GAAP        | US-GAAP        | US-GAAP        |
| Employees           |                |                |                | 8,030          | 8,200          | 7,900          |
| Equity ratio        |                |                |                | 71.07%         | 71.22%         | 76.89%         |
| Debt-equity ratio   |                |                |                | 40.70%         | 40.42%         | 30.06%         |
|                     |                |                |                |                |                |                |
| Others              |                |                |                |                |                |                |
|                     |                |                |                | 2023           | 2022           | 2021           |
| Tax Expense Rate    |                |                |                | 25.03%         | 22.89%         | 21.92%         |

# **BIO-RAD LABORATORIES INC.**

ISIN: US0905722072 WKN: 090572207 Asset Class: Stock

| Income statement                                             |               |                |               |
|--------------------------------------------------------------|---------------|----------------|---------------|
|                                                              | 2023          | 2022           | 2021          |
| Turnover                                                     | 2,671,262,000 | 2,802,249,000  | 2,922,545,000 |
| Net income                                                   | -637,324,000  | -3,627,535,000 | 4,245,902,000 |
| EBIT                                                         | -832,414,965  | -4,361,816,005 | 5,005,024,640 |
| Operating income before taxes                                | -850,104,000  | -4,704,273,000 | 5,438,149,000 |
| Cash Flow                                                    | 374,943,000   | 1,436,047,000  | -425,779,000  |
| Net interest income                                          | 51,461,000    | 19,886,000     | 17,349,000    |
| Research and development expenses                            | 226,927,000   | 256,789,000    | 258,357,000   |
| Income taxes                                                 | -212,780,000  | -1,076,738,000 | 1,192,247,000 |
| Result from investments in subsidaries, associates and other | 0             | 0              | 0             |
| Revenues per employee                                        | 307,145       | 315,526        | 341,568       |

# **Board of Directors**

| Members of Mana    | agement Board                 |   |
|--------------------|-------------------------------|---|
| Alice Schwartz     | Member of Board of Directors  | _ |
| Allison Schwartz   | Member of Board of Directors  |   |
| Arnold Pinkston    | Member of Board of Directors  |   |
| Gregory Hinckley   | Member of Board of Directors  |   |
| Jeffrey Edwards    | Member of Board of Directors  |   |
| Melinda Litherland | Member of Board of Directors  |   |
| Norman Schwartz    | Chairman of Managing Board    |   |
| Ajit Ramalingam    | Member of Executive Committee |   |
| Andrew Last        | Member of Executive Committee |   |
| Annette Tumolo     | Member of Executive Committee |   |
| Dara Wright        | Member of Executive Committee |   |
| Ilan Daskal        | Member of Executive Committee |   |
| Mike Crowley       | Member of Executive Committee |   |
| Timothy Ernst      | Member of Executive Committee |   |
|                    |                               |   |